DADamien Ambrosetti

Damien Ambrosetti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Damien Ambrosetti has a total of 736 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Educational Impact of an Instagram Account on Histology Teaching: Mixed Methods Approach in Medical Education

    by Fatéméh Dubois, Damien Ambrosetti, Lucie Tosca

    Background: Morphology-based disciplines such as histology, embryology, and cytogenetics require strong visual learning and rely heavily on visual pattern recognition, with more complex integrative processes, that is, higher-order cognitive skills that connect, interpret, and apply knowledge across contexts. These skills may be supported by social media formats. In parallel, medical students increasingly engage with digital and social media platforms, prompting interest in their potential educational value. Instagram (Meta Platforms, Inc), as an image-centered and interactive medium, has emerged as a potential pedagogical tool. The Histo.Embryo Instagram account was launched in 2023 under the auspices of the French National College of Histologists, Embryologists, and Cytogeneticists (CHEC) to complement traditional teaching with bilingual, interactive, image-based posts. Objective: This study aimed to evaluate the pedagogical contribution of the Histo.Embryo Instagram account with a focus on students’ engagement, usage patterns, perceived learning outcomes, and qualitative user experience. This learning platform was developed as a visual and interactive tool to complement traditional teaching in histology, embryology, and cytogenetics. Methods: A mixed methods design combined a structured online survey (N>100), Instagram analytics (90-day period), and qualitative feedback. Quantitative data assessed usage frequency, preferred content formats, perceived utility, and self-reported learning outcomes. Qualitative data were analyzed thematically to explore how students interacted with and integrated the content into their learning practices. Results: Instagram was the dominant platform among students, with 81% (101/125) reporting daily use. The account reached 2582 unique users and 168,778 views. Static quiz-based posts generated 96% (203/207) of engagement, highlighting a strong preference for active recall formats. Survey data showed that 98% (122/125) perceived improved understanding, 64% (80/125) enhanced visual recognition, and over two-thirds reused content in academic settings. Qualitative findings provided additional insight into these patterns. Students described the content as accessible, visually clear, and aligned with exam expectations, emphasizing its role in simplifying complex concepts and supporting memorization. Many reported using posts for rapid revision, self-assessment, and consolidation of prior knowledge, suggesting integration into self-regulated learning strategies. The interactive quiz format was perceived as motivating and cognitively engaging. Conclusions: The Histo.Embryo Instagram account suggests that Instagram, when intentionally structured, may complement traditional teaching by supporting visual learning, active recall, and flexible study practices. Nevertheless, these findings should be interpreted cautiously due to potential self-selection bias, reliance on subjective measures, and the absence of controlled comparisons. Further research is needed to evaluate its impact on objective learning outcomes and long-term knowledge retention.

  • Carcinomes rénaux : caractérisation moléculaire et des voies métaboliques dépendant des mécanismes hypoxiques

    by Damien Ambrosetti

    Les carcinomes rénaux (RCC) sont subdivisés en plusieurs sous-types, définis selon des critères histologiques, phénotypiques et génétiques. Le diagnostic différentiel de ces tumeurs est primordial avec des conséquences pronostiques et thérapeutiques. Génétique et diagnostic : Nous avons étudié les données cliniques, histologiques, immunohistochimiques et génétiques d'une série de RCC papillaires (PRCC) de type 1 et 2. Une caractérisation génomique exhaustive complétée par NGS nous a permis de classer les PRCC de type 2 dans plusieurs groupes d'évolution variable. Nos résultats fournissent des informations inédites sur la pathogenèse des PRCC qui donnent des pistes pour un traitement personnalisé. Métabolisme, grade tumoral et phénotype : Dans une série de RCC à cellules claires (ccRCC), nous avons analysé les caractéristiques de ces tumeurs et l'expression des protéines impliquées dans le métabolisme et les isoformes de HIF. Cette étude nous a permis de mettre en évidence quantitativement une corrélation entre l'expression de MCT1, GLUT1 et CAXII et le grade de Fuhrman, et qualitativement une localisation périphérique de HIF2alpha et la co-localisation des protéines HIF2alpha et HAF. Stratégies théranostiques : Dans l’optique de définir les traitements les plus appropriés pour les patients atteints de RCC, nous avons fait un parallèle entre la sensibilité aux thérapies ciblées des patients (in vivo) et de cellules dérivées de la tumeur initiale (in vitro). Nous avons démontré que la réponse chez les patients et dans les cellules était équivalente et donc que des tests in vitro sont une piste pour définir des traitements personnalisés des patients atteints de ccRCC.

  • Open Access

    Hypusination of the translation factor eIF5A regulates mitochondrial tRNA processing to promote prostate cancer aggressiveness

    by Michel Kahi, Abigail Mazzu′, Ludovic Batistic, Marc Pujalte-Martin, Victor Tiroille, Anne Vincent, Joseph Murdaca, Loic Trapani, Paraskevi Kousteridou, Oumayma Benaceur, et al.

    Protein synthesis plays a central role in cancer development and progression. eukaryotic initiation factor 5 A (eIF5A), a translation factor activated by hypusination, is implicated in tumorigenesis, however, its mode of action is still unclear. We find that hypusinated eIF5A (eIF5Ahyp) promotes metastasis and tumor growth in prostate cancer (PCa) by supporting mitochondrial metabolism and translation. eIF5Ahyp controls the subcellular localization of Mitochondrial Ribonuclease P Protein 3 (MRPP3) mRNA encoding a protein essential for mitochondrial tRNA (mt-tRNA) maturation. We show that eIF5Ahyp regulates the nuclear export of MRPP3 mRNA, its expression, thereby promoting mt-tRNA maturation. Our findings establish that MRPP3 enhances mitochondrial metabolism and supports PCa metastasis. Importantly, its expression restores mitochondrial translation and tumor growth inhibited by the downregulation of eIF5Ahyp. Together, we uncover a critical role for eIF5Ahyp in mitochondrial protein synthesis and highlight its broader implications in coordinating the expression of nuclear and mitochondrial genomes, linking hypusination to cancer progression.


  • Renal Cell Carcinoma subtyping: Learning from multi-resolution localization

    by Mohamad Mohamad, Francesco Ponzio, Santa Di Cataldo, Damien Ambrosetti, Xavier Descombes


  • Open Access

    Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001

    by Christopher Montemagno, Arnaud Jacquel, Charlotte Pandiani, Olivia Rastoin, Rosie Dawaliby, Thomas Schmitt, Maxence Bourgoin, Héliciane Palenzuela, Anne-Laure Rossi, Damien Ambrosetti, et al.

    Background: In clear cell renal cell carcinoma (ccRCC), first-line treatment combines nivolumab (anti-PD-1) and ipilimumab (anti-CTLA4), yielding long-term remissions but with only a 40% success rate. Our study explored the potential of enhancing ccRCC treatment by concurrently using CXCR2 inhibitors alongside immunotherapies. Methods: We analyzed ELR + CXCL levels and their correlation with patient survival during immunotherapy. RCT001, a unique CXCR2 inhibitor, was examined for its mechanism of action, particularly its effects on human primary macrophages. We tested the synergistic impact of RCT001 in combination with immunotherapies in both mouse models of ccRCC and human ccRCC in the presence of human PBMC. Resuts: Elevated ELR + CXCL cytokine levels were found to correlate with reduced overall survival during immunotherapy. RCT001, our optimized compound, acted as an inverse agonist, effectively inhibiting angiogenesis and reducing viability of primary ccRCC cells. It redirected M2-like macrophages without affecting M1-like macrophage polarization directed against the tumor. In mouse models, RCT001 enhanced the efficacy of anti-CTLA4 + anti-PD1 by inhibiting tumor-associated M2 macrophages and tumor-associated neutrophils. It also impacted the activation of CD4 T lymphocytes, reducing immune-tolerant lymphocytes while increasing activated natural killer and dendritic cells. Similar effectiveness was observed in human RCC tumors when RCT001 was combined with anti-PD-1 treatment. Conclusions: RCT001, by inhibiting CXCR2 through its unique mechanism, effectively suppresses ccRCC cell proliferation, angiogenesis, and M2 macrophage polarization. This optimization potentiates the efficacy of immunotherapy and holds promise for significantly improving the survival prospects of metastatic ccRCC patients.


  • Open Access

    Machine‐learning approach for prediction of pT3a upstaging and outcomes of localized renal cell carcinoma ( UroCCR ‐15)

    by Astrid Boulenger de Hauteclocque, Loïc Ferrer, Damien Ambrosetti, Solene Ricard, Pierre Bigot, Karim Bensalah, François Henon, Nicolas Doumerc, Arnaud Méjean, Virginie Verkarre, et al.

    Objectives: To assess the impact of pathological upstaging from clinically localized to locally advanced pT3a on survival in patients with renal cell carcinoma (RCC), as well as the oncological safety of various surgical approaches in this setting, and to develop a machine‐learning‐based, contemporary, clinically relevant model for individual preoperative prediction of pT3a upstaging. Materials and Methods: Clinical data from patients treated with either partial nephrectomy (PN) or radical nephrectomy (RN) for cT1/cT2a RCC from 2000 to 2019, included in the French multi‐institutional kidney cancer database UroCCR, were retrospectively analysed. Seven machine‐learning algorithms were applied to the cohort after a training/testing split to develop a predictive model for upstaging to pT3a. Survival curves for disease‐free survival (DFS) and overall survival (OS) rates were compared between PN and RN after G‐computation for pT3a tumours. Results: A total of 4395 patients were included, among whom 667 patients (15%, 337 PN and 330 RN) had a pT3a‐upstaged RCC. The UroCCR‐15 predictive model presented an area under the receiver‐operating characteristic curve of 0.77. Survival analysis after adjustment for confounders showed no difference in DFS or OS for PN vs RN in pT3a tumours (DFS: hazard ratio [HR] 1.08, P = 0.7; OS: HR 1.03, P > 0.9). Conclusions: Our study shows that machine‐learning technology can play a useful role in the evaluation and prognosis of upstaged RCC. In the context of incidental upstaging, PN does not compromise oncological outcomes, even for large tumour sizes.


  • Open Access

    New splice variants of VEGF as relevant targets for the treatment of renal cell carcinoma

    by Christopher Montemagno, Jérôme Durivault, Cécile Gastaldi, Maeva Dufies, Valérie Vial, Xingkang He, Damien Ambrosetti, Anna Kamenskaya, Sylvie Négrier, Jean Christophe Bernhard, et al.

    Background The efficacy of anti-VEGF/VEGF receptors in the treatment of metastatic clear cell renal cell carcinoma (ccRCC) varies from patient to patient. Discovering the reasons for this variability could lead to the identification of relevant therapeutic targets. We have investigated the possibility of splicing events leading to new forms of VEGF that are less efficiently inhibited by anti-VEGF/VEGFR targeting the conventional forms. Methods In silico analysis identified the presence of an unknown splice acceptor in the last intron of the VEGF gene resulting in an insertion of 23 bases in VEGF mRNA. Such an insertion can occur in previously described splice variants of VEGF (VEGFXXX) and shift the open reading frame, leading to a change in the c-terminal part of VEGF. We investigated the role of the resulting new major form of VEGF, VEGF222NF, in physiological and pathological angiogenesis. We analyzed the expression of these new alternatively spliced forms in normal tissue and in a series of RCC cells by qPCR and ELISA. We generated experimental RCC in mice by implanting ccRCC cells overexpressing VEGF222NF. The experimental RCC were also treated with polyclonal anti-VEGF/NF antibodies. The relationship between plasmatic VEGF/NF levels and resistance to anti-VEGFR and survival was also investigated in a cohort of patients from the NCT00943839 clinical trial. Results VEGF222/NF stimulated endothelial cell proliferation and vascular permeability through activation of VEGFR2. Overexpression of VEGF222/NF stimulated proliferation and metastatic properties of RCC cells, whereas its downregulation resulted in cell death. RCC cells overexpressing VEGF222/NF generated aggressive experimental tumors that developed functional blood and lymphatic vessels. Anti-VEGFXXX/NF antibodies slowed the growth of experimental RCC by inhibiting tumor cell proliferation and the development of blood and lymphatic vessels. High plasmatic VEGFXXX/NF levels correlated with shorter survival and lower efficacy of anti-angiogenic drugs. Conclusions The existence of new VEGF isoforms has shed new light on the VEGF field.

  • Open Access

    MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights

    by Audrey Simonaggio, Damien Ambrosetti, Virginie Verkarre, Marie Auvray, Stéphane Oudard, Yann-Alexandre Vano

    MiTF/TFE translocation renal cell carcinoma (tRCC) is a rare and aggressive subtype of RCC representing the most prevalent RCC in the pediatric population (up to 40%) and making up 4% of all RCCs in adults. It is characterized by translocations involving either TFE3 (TFE3-tRCC), TFEB (TFEB-tRCC) or MITF, all members of the MIT family (microphthalmia-associated transcriptional factor). TFE3-tRCC was first recognized in the World Health Organization (WHO) classification of kidney cancers in 2004. In contrast to TFEB-tRCC, TFE3-tRCC is associated with many partners that can be detected by RNA or exome sequencing. Both diagnoses of TFE3 and TFEB-tRCC are performed on morphological and immunohistochemical features, but, to date, TFE break-apart fluorescent in situ hybridization (FISH) remains the gold standard for diagnosis. The clinical behavior of tRCC is heterogeneous and more aggressive in adults. Management of metastatic tRCC is challenging, especially in the younger population, and data are scarce. Efficacy of the standard of care-targeted therapies and immune checkpoint inhibitors remains low. Recent integrative exome and RNA sequencing analyses have provided a better understanding of the biological heterogeneity, which can contribute to a better therapeutic approach. We describe the clinico-pathological entities, the response to systemic therapy and the molecular features and techniques used to diagnose tRCC.


  • Identifying regions of interest in whole slide images of renal cell carcinoma

    by Mohammed Lamine Benomar, Nesma Settouti, Eric Debreuve, Xavier Descombes, Damien Ambrosetti


  • Cancer‐associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti‐angiogenic therapy

    by Damien Ambrosetti, Michael Coutts, Charlotte Paoli, Matthieu Durand, Delphine Borchiellini, Christopher Montemagno, Olivia Rastoin, Arnaud Borderie, Renaud Grepin, Nathalie Rioux‐Leclercq, et al.

    Objectives: To investigate the role of cancer‐associated fibroblasts (CAFs) in clear cell renal cell carcinoma (ccRCC) with respect to tumour aggressiveness, metastasis development, and resistance to anti‐angiogenic therapy (vascular endothelial growth factor receptor‐tyrosine kinase inhibitors [VEGFR‐TKI]). Patients and Methods: Our study involved tissue samples from three distinct and independent cohorts of patients with ccRCC. The presence of CAFs and tumour lymphangiogenesis was investigated, respectively, by transcriptional signatures and then correlated with tumour development and prognosis. The effect of these CAFs on tumour cell migration and VEGFR‐TKI resistance was analysed on co‐cultures of ccRCC cells with CAFs. Results: Results from our cohorts and from in silico investigations showed that VEGFR‐TKI significantly increase the number of CAFs in tumours. In the same populations of patients with ccRCC, the proportion of intra‐tumoral CAFs correlated to shorter disease‐free and overall survival. The presence of CAFs was also correlated with lymphangiogenesis and lymph node metastasis. CAFs increased the migration and decreased the VEGFR‐TKI‐dependent cytotoxic effect of tumour cells. Conclusions: Our results show that VEGFR‐TKI promote the development of CAFs, and CAFs favour tumour aggressiveness, metastatic dissemination, and resistance to treatment in ccRCC. CAFs could represent a new therapeutic target to fight resistance to treatment of ccRCC. Targeting CAF and immunotherapies combination are emerging as efficient treatments in many types of solid tumours. Our results highlight their relevance in ccRCC.